Table 2 Initial demographic and clinical features associated with mortality
From: Enigma of COVID-19: is “multisystem inflammatory syndrome in adults” (MIS-A) predictable?
Survival | Univariable Cox Regression | ||||
|---|---|---|---|---|---|
Alive n = 2169 | Exitus n = 164 | HR | 95% CI | p | |
Age, years | 58.8 ± 16.4 | 67.9 ± 14.5 | 1.03 | 1.02–1.04 | < 0.001 |
Gender, n (%) | |||||
Female | 1041 (48.0) | 79 (48.2) | |||
Male | 1128 (52.0) | 85 (51.8) | 1.01 | 0.74–1.38 | 0.937 |
Comorbidity, n (%) | |||||
DM | 603 (27.8) | 59 (36.0) | 1.34 | 0.97–1.84 | 0.074 |
HT | 897 (41.4) | 73 (44.5) | 1.09 | 0.8–1.48 | 0.598 |
CRF | 172 (7.9) | 24 (14.6) | 1.22 | 0.79–1.9 | 0.368 |
CAD | 389 (17.9) | 41 (25.0) | 1.29 | 0.91–1.85 | 0.155 |
COPD | 162 (7.5) | 12 (7.3) | 0.77 | 0.43–1.39 | 0.388 |
Malignancy | 172 (7.9) | 25 (15.2) | 1.43 | 0.93–2.21 | 0.107 |
Presence of typical COVID-19 Involvement | 1751 (80.7) | 148 (90.2) | 1.92 | 1.15–3.22 | 0.013 |
Laboratory findings | |||||
Hemoglobin (gr/dL) | 12.6 ± 2.1 | 12 ± 2.1 | 0.97 | 0.9–1.04 | 0.351 |
Plateler, × 103/mm3 | 215 (1–1555) | 190.5 (1.1–667) | 0.98 | 0.97–0.99 | 0.006 |
Leukocyte, × 103/mm3 | 6.5 (0.1–124.4) | 7 (0.6–37.6) | 1.02 | 1.01–1.04 | 0.021 |
Neutrophil, × 103/mm3 | 4.2 (0–42.4) | 5.7 (0.2–35.8) | 1.07 | 1.04–1.10 | < 0.001 |
Lymphocyte, × 103 | 1.3 (0.2–17.9) | 0.9 (0.2–2.1) | 0.23 | 0.16–0.34 | < 0.001 |
LDH (IU/L) | 246.6 (37–1877) | 341.5 (104–1293) | 1.02 | 1.01–1.03 | < 0.001 |
LLR | 0.2 (0–0.7) | 0.4 (0.1–4.2) | 2.67 | 2.19–3.25 | < 0.001 |
CRP (mg/dL) | 35 (0.2–400) | 95 (2.8–429) | 1.06 | 1.04–1.08 | < 0.001 |
Procalcitonin (ng/ml) | 0.1 (0–81.7) | 0.2 (0–53.3) | 1.02 | 0.98–1.04 | 0.084 |
Urea (mg/dL) | 32 (6–442) | 47 (14–229.4) | 1.06 | 1.03–1.09 | < 0.001 |
Creatinine (mg/dL) | 0.8 (0.1–29.4) | 1 (0.4–7.3) | 1.00 | 0.91–1.09 | 0.923 |
AST (IU/L) | 26 (3–2524) | 31 (11.4–229) | 1.00 | 0.97–1.05 | 0.544 |
ALT (IU/L) | 21 (1–2034) | 22 (1–176) | 1.00 | 0.99–1.01 | 0.245 |
Total protein (gr/dL) | 68.3 ± 7.2 | 67.2 ± 8.1 | 0.99 | 0.97–1.01 | 0.228 |
Albumin (gr/L) | 36.7 ± 5.1 | 33.9 ± 6.2 | 0.95 | 0.93–0.98 | < 0.001 |
CK (IU/L) | 74 (1–7290) | 115.5 (17–3303) | 1.04 | 1.02–1.07 | 0.001 |
D-dimer | 0.7 (0–36) | 1 (0.1–35.4) | 1.04 | 1.01–1.07 | 0.019 |
Ferritin (mcg/L) | 151.2 (2–5900) | 327 (7.4–3247) | 1.07 | 1.05–1.10 | < 0.001 |
Fibrinojen (mg/dL) | 472 (0.7–12,000) | 602 (170–1355) | 1.02 | 1.01–1.04 | 0.011 |
Presence of Resistant Fever, n (%) | 94 (4.3) | 25 (15.2) | 1.15 | 0.73–1.81 | 0.549 |
MIS-A, n (%) | 150 (6.9) | 82 (50.0) | 4.27 | 3.08–5.92 | < 0.001 |
Time to blood sampling, days (range) | 10 (4–22) | 4 (1–12) | 1.06 | 1.01–1.05 | < 0.001 |
Time to MIS-A, days (range) | 4 (1–26) | 3 (1–20) | 0.87 | 0.84–0.90 | < 0.001 |
Follow up duration, days | 6 (1–52) | 7 (1–54) | – | – | – |